Breast and prostate cancer treatment method

Details Breast and prostate cancer treatment method Breast and prostate cancer treatment method

2011-01-04

2011-01-04

Hui, San-ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C552S502000

Reexamination Certificate

active

07863261

ABSTRACT:
The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.

REFERENCES:
patent: 2243887 (1941-06-01), Serini et al.
patent: 2251939 (1941-08-01), Kathol
patent: 2266778 (1941-12-01), Logemann et al.
patent: 2267257 (1941-12-01), Ruzicka
patent: 2308833 (1943-01-01), Ruzicka et al.
patent: 2308834 (1943-01-01), Ruzicka et al.
patent: 2318105 (1943-05-01), Ruzicka
patent: 2357364 (1944-09-01), Stavely
patent: 3029263 (1962-04-01), Campbell et al.
patent: 3210249 (1965-10-01), Beerstecher et al.
patent: 3336347 (1967-08-01), Engelfried et al.
patent: 3459739 (1969-08-01), Borrevang et al.
patent: 3654320 (1972-04-01), Ayer et al.
patent: 3734935 (1973-05-01), Husbands et al.
patent: 3869467 (1975-03-01), Guthrie et al.
patent: 3935245 (1976-01-01), Engelfried et al.
patent: 3944576 (1976-03-01), Van den Broek
patent: 3962275 (1976-06-01), Guthrie et al.
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 5028631 (1991-07-01), Schwartz et al.
patent: 5075464 (1991-12-01), Blohm
patent: 5206008 (1993-04-01), Loria
patent: 5237064 (1993-08-01), Bakshi et al.
patent: 5292730 (1994-03-01), Lardy
patent: 5296481 (1994-03-01), Partridge et al.
patent: 5372996 (1994-12-01), Labrie
patent: 5387583 (1995-02-01), Loria
patent: 5424463 (1995-06-01), Lardy et al.
patent: 5461042 (1995-10-01), Loria
patent: 5478566 (1995-12-01), Loria
patent: 5506223 (1996-04-01), Lardy et al.
patent: 5532230 (1996-07-01), Daynes et al.
patent: 5567830 (1996-10-01), Upasani
patent: 5593981 (1997-01-01), Labrie
patent: 5656621 (1997-08-01), Schwartz et al.
patent: 5686438 (1997-11-01), Daynes et al.
patent: 5744462 (1998-04-01), Schwartz et al.
patent: 5763433 (1998-06-01), Morfin
patent: 5859000 (1999-01-01), Dowell et al.
patent: 5912240 (1999-06-01), Loria
patent: 5922701 (1999-07-01), Araneo
patent: 5925630 (1999-07-01), Upasani et al.
patent: 5981744 (1999-11-01), Ng et al.
patent: 5994335 (1999-11-01), Brodie et al.
patent: 6440966 (2002-08-01), Barrett et al.
patent: 6573289 (2003-06-01), Tasaka et al.
patent: 6667299 (2003-12-01), Ahlem et al.
patent: 6696459 (2004-02-01), Jones et al.
patent: 6767903 (2004-07-01), Cleve et al.
patent: 6770639 (2004-08-01), Snow et al.
patent: 6770641 (2004-08-01), Hayakawa et al.
patent: 6790842 (2004-09-01), Bohlmann et al.
patent: 6962923 (2005-11-01), Banks et al.
patent: 7482334 (2009-01-01), Frincke et al.
patent: 7524835 (2009-04-01), Frincke
patent: 2003/0060425 (2003-03-01), Ahlem et al.
patent: 2004/0043973 (2004-03-01), Ahlem et al.
patent: 2004/0097406 (2004-05-01), Ahlem et al.
patent: 2004/0116359 (2004-06-01), Ahlem et al.
patent: 2004/0220114 (2004-11-01), Ahlem et al.
patent: 2004/0242618 (2004-12-01), Lardy et al.
patent: 2005/0159366 (2005-07-01), Ahlem et al.
patent: 2005/0256095 (2005-11-01), Ahlem et al.
patent: 2005/0282732 (2005-12-01), Ahlem et al.
patent: 2006/0063749 (2006-03-01), Ahlem et al.
patent: 2006/0073099 (2006-04-01), Frincke et al.
patent: 2006/0079492 (2006-04-01), Ahlem et al.
patent: 2006/0088473 (2006-04-01), Dowding et al.
patent: 2007/0014719 (2007-01-01), Reading et al.
patent: 2007/0077201 (2007-04-01), Reading et al.
patent: 2007/0129282 (2007-06-01), Ahlem et al.
patent: 2008/0004250 (2008-01-01), Lardy et al.
patent: 2008/0009472 (2008-01-01), Lardy et al.
patent: 2008/0021006 (2008-01-01), Lardy et al.
patent: 2008/0058301 (2008-03-01), Lardy et al.
patent: 2008/0070881 (2008-03-01), Lardy et al.
patent: 2008/0153792 (2008-06-01), Frincke et al.
patent: 2008/0176823 (2008-07-01), Frincke et al.
patent: 2008/0176824 (2008-07-01), Frincke et al.
patent: 1054143 (1979-05-01), None
patent: 0 363 128 (1990-04-01), None
patent: WO 95/07926 (1995-03-01), None
patent: WO 95/10527 (1995-04-01), None
patent: WO 97/37662 (1997-10-01), None
patent: WO 99/63973 (1999-12-01), None
Ben-David et al., Anti-hypocholterolemic effects of dihydroepiandersterone in ratsProc. Soc. Exp. Biol. Med., 125:1136-40 1967.
Clinton, et al., Esters of 17α-Ethinylandrostane-3β,17β-diol and 17α-ethinylandrost-5-ene-3β,17β-diol,J. Org. Chem. 22:473-475 1957.
Gatto, et al., Dehydroepiandrosterone inhibits the growth of DMBA-induced rat mammary carcinoma via the androgen receptorOncol. Rep. 5(1): 241-3 1998.
Irmsher, et al, Preparation of 7α-Hydroxy- and 7α-Methoxytestosterone DerivativesChem. Ber. 97:3363-3373 1964 (translated from German).
Marshall, et al, 7-Keto steroids. II. Steroidal 3-β-hydroxy-Δ5-7-ones and Δ3,5-7-onesJ. Amer. Chem. Soc. 79:6308-6313 1957.
Moore, et al. Concentration of dihydrotestosterone and 3α-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog J.Clin. Invest. 64:1003-1010 1979.
Ranney et a.,l Hypocholesterolemic effect of an androsterone analogProc. Soc. Exp. Biol. Med. 166:569-9 1964.
Rao, et al., Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone, Cancer Res. 59(13):3084-3089, 1999.
Schwarz, Concerning Steroid Derivatives XIV Preparation of Methylandrostenediol Derivatives with an Oxygen Function at the 7 PositionColl. Czech. Chem. Comm. 26:1958-1966 1961 (translated from German).
Chang, et al., Suppression of Δ5-Androstenediol-induced androgen receptor transactlvation by selective steroids in human prostate cancer cells,Proc. Natl. Acad. Sci. USA., 96(20):11173-11177, Sep. 28, 1999.
Hackenberg et al., Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3β,17β-diol in human mammary cancer cells,J. Steroid Biochem. Molec. Biol., 46(5):597-603 1993.
Henderson, Dehydroepiandrosterone and 16α-bromo-epiandrosterone: Inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes,Carcinogenesis, 2(7):683-686 1981.
Lardy, et al., Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone,Steroids, 63:158-165 1998.
Miyamoto, et al., Δ5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells,Proc. Natl. Acad. Sci. U. S A. 95(19):11083-11088 1998.
Miyamoto, et al.,3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity,Proc. Natl. Acad. Sci. USA, 100:4440-4444, 2003.
Pashko, et al., Dehydroepiandrosterone (DHEA) and 3 beta-methylandrost-5-en-17-one: inhibitors of 7,12-dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice,Carcinogenesis5(4):463-466 1984.
Segaloff, et al, Hormonal therapy in cancer of the breast II. Effect of methylandrostenediol on clinical course and hormonal excretion,Cancer, 5(2):271-74 1952.
Segaloff, et al, Hormonal therapy in cancer of the breast IV. Effect of androstenediol on clinical course and hormonal excretion,Cancer, 5(6):271-74 1952.
Segaloff, et al, Hormonal therapy in cancer of the breast. V. The effect of methyltestosterone on clinical course and hormonal excretion,Cancer, 6(3):483-487 1953.
Segaloff, et al, Testosterone and miscellaneous steroids in the treatment of advanced mammary cancer,Cancer, 10(4):808-812 1957.
U.S. Appl. No. 11/835,394, filed Aug. 7, 2007, Frincke, et al.
Chambaz, et al., Urinary steroids in neonates: Characterization of four androstenetetrols by gas chromatography and mass spectrometry.Proceedings of Acad. Sc. Paris, Series D, 268: 2817-??? 1969.
Chang, et al., Suppression of A§ -Androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells,Proc. Natl. Acad. Sci. USA. 96(20):11173-11177, Sep. 28, 1999.
Kroboth, et al DHEA and DHEA-S: A review,J. Clin. Pharm. 39:327-348 1999.
Lardy, et al., Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosteroneSteroid

Affiliated with

Also associated with

Rating

Breast and prostate cancer treatment method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Breast and prostate cancer treatment method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breast and prostate cancer treatment method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2627452